Tags

Type your tag names separated by a space and hit enter

Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context.
Arch Intern Med. 2004 Mar 08; 164(5):486-91.AI

Abstract

Type 2 diabetes mellitus is the consequence of both insulin resistance and impaired insulin secretion. In the progression from normal glucose tolerance to diabetes, postprandial glucose (PPG) levels often rise before fasting plasma glucose (FPG) levels increase above 126 mg/dL (7.0 mmol/L). Numerous epidemiologic studies have shown that impaired glucose tolerance is associated with increased risk for macrovascular disease and that isolated postchallenge hyperglycemia is an independent factor for increased mortality. Reducing the risk for microvascular complications by improving glycosylated hemoglobin (HbA(1c)) levels is well documented. Emerging data now support the relationship between glycemic control and macrovascular disease. Epidemiologic studies documenting postprandial hyperglycemia and the risk for increased mortality suggest that lowering PPG levels might be beneficial. Optimizing both FPG and PPG is important in achieving normal/near-normal glucose levels. Many patients with type 2 diabetes have difficulty attaining the recommended HbA(1c) goal despite normal/near-normal FPG levels; thus, pharmacologic treatment targeting PPG levels may prove beneficial.

Authors+Show Affiliations

Joslin Diabetes Center and Department of Medicine, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA. Martin.Abrahamson@joslin.harvard.edu

Pub Type(s)

Journal Article

Language

eng

PubMed ID

15006824

Citation

Abrahamson, Martin J.. "Optimal Glycemic Control in Type 2 Diabetes Mellitus: Fasting and Postprandial Glucose in Context." Archives of Internal Medicine, vol. 164, no. 5, 2004, pp. 486-91.
Abrahamson MJ. Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. Arch Intern Med. 2004;164(5):486-91.
Abrahamson, M. J. (2004). Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. Archives of Internal Medicine, 164(5), 486-91.
Abrahamson MJ. Optimal Glycemic Control in Type 2 Diabetes Mellitus: Fasting and Postprandial Glucose in Context. Arch Intern Med. 2004 Mar 8;164(5):486-91. PubMed PMID: 15006824.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Optimal glycemic control in type 2 diabetes mellitus: fasting and postprandial glucose in context. A1 - Abrahamson,Martin J, PY - 2004/3/10/pubmed PY - 2004/3/31/medline PY - 2004/3/10/entrez SP - 486 EP - 91 JF - Archives of internal medicine JO - Arch Intern Med VL - 164 IS - 5 N2 - Type 2 diabetes mellitus is the consequence of both insulin resistance and impaired insulin secretion. In the progression from normal glucose tolerance to diabetes, postprandial glucose (PPG) levels often rise before fasting plasma glucose (FPG) levels increase above 126 mg/dL (7.0 mmol/L). Numerous epidemiologic studies have shown that impaired glucose tolerance is associated with increased risk for macrovascular disease and that isolated postchallenge hyperglycemia is an independent factor for increased mortality. Reducing the risk for microvascular complications by improving glycosylated hemoglobin (HbA(1c)) levels is well documented. Emerging data now support the relationship between glycemic control and macrovascular disease. Epidemiologic studies documenting postprandial hyperglycemia and the risk for increased mortality suggest that lowering PPG levels might be beneficial. Optimizing both FPG and PPG is important in achieving normal/near-normal glucose levels. Many patients with type 2 diabetes have difficulty attaining the recommended HbA(1c) goal despite normal/near-normal FPG levels; thus, pharmacologic treatment targeting PPG levels may prove beneficial. SN - 0003-9926 UR - https://www.unboundmedicine.com/medline/citation/15006824/Optimal_glycemic_control_in_type_2_diabetes_mellitus:_fasting_and_postprandial_glucose_in_context_ L2 - https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/10.1001/archinte.164.5.486 DB - PRIME DP - Unbound Medicine ER -